Peptides Mentioned by Brigham Buhler on Joe Rogan Experience #2469
Buhler and Rogan returned to peptide regulation, pharmacy quality, patent incentives and the gray market. The episode names six compounds or products. Their on-air opinions and personal reports are separated below from approved indications and clinical evidence.
#2469 — Brigham Buhler
Guest: Brigham Buhler · Released March 18, 2026
Watch the official PowerfulJRE episodeHow this article was verified
The official 2:22:01 PowerfulJRE episode confirms #2469, Brigham Buhler as the guest, and March 18, 2026 as the release date. Its public transcript supports the six compounds or products covered below. This page is limited to this selected episode and does not claim to catalogue every peptide ever discussed on JRE.
Compounds discussed in this episode
Speaker claims below are paraphrases, not endorsements or quotations. Scientific context is separated from the speaker's experience or opinion.
01BPC-157
What the speaker said
Buhler used BPC-157 to argue that naturally occurring short-chain molecules can be difficult to patent and therefore unattractive to fund through expensive approval programs. Rogan imagined how availability and advertising might change after approval. Neither speaker supplied new human trial evidence for the injury claims mentioned in that hypothetical.
Scientific Context
The funding argument does not establish efficacy. BPC-157 injury and gastrointestinal claims continue to rely predominantly on preclinical studies, with no FDA-approved indication and inadequate controlled human safety evidence.
Where to buy for laboratory research
BPC-157 at Base Peptides — verified exact-name product page. This editorial listing is not a guest endorsement and is not a recommendation for human use.
02CJC-1295
What the speaker said
Rogan referred to a CJC/ipamorelin combination while describing a flushing sensation that some users take as evidence that a product is active. Subjective flushing cannot authenticate identity, purity or dose.
Scientific Context
CJC-1295 is form-dependent: DAC and no-DAC materials have different kinetics. The conversation did not resolve the form, and a bodily sensation is not an analytical test or proof of clinical benefit.
Where to buy for laboratory research
No product is linked because the episode does not specify DAC versus no-DAC; the verified Base Peptides page is specifically CJC-1295 DAC. No substitute or near-match is linked.
03Ipamorelin
What the speaker said
Ipamorelin was named as the other half of the CJC combination. Rogan's comment concerned users' perceived acute response, not a measured recovery, body-composition or longevity outcome.
Scientific Context
Ipamorelin can stimulate growth-hormone release, but that pharmacologic response does not establish broad wellness benefits or long-term safety.
Where to buy for laboratory research
Ipamorelin at Base Peptides — verified exact-name product page. This editorial listing is not a guest endorsement and is not a recommendation for human use.
04Dihexa
What the speaker said
Buhler clearly framed this as personal experience: he said prescribed Dihexa improved his neurocognitive function, recall and retention. That is an anecdote from one speaker, not a controlled finding.
Scientific Context
Dihexa has interesting preclinical synaptogenesis research but lacks published, replicated human clinical evidence establishing cognitive benefit or long-term safety.
Where to buy for laboratory research
Dihexa at Base Peptides — verified exact-name product page. This editorial listing is not a guest endorsement and is not a recommendation for human use.
05Retatrutide
What the speaker said
Buhler identified retatrutide as Eli Lilly's investigational triple agonist and tied enforcement attention to gray-market demand. He made favorable comparative safety, muscle-wasting and fat-loss claims while also acknowledging it had not completed Phase 3 or reached the market.
Scientific Context
Retatrutide remains investigational. Published Phase 2 results cannot establish final safety, approval, superiority on muscle preservation, or the identity of any gray-market vial.
Where to buy for laboratory research
Retatrutide at Base Peptides — verified exact-name product page. This editorial listing is not a guest endorsement and is not a recommendation for human use.
06Ozempic (semaglutide)
What the speaker said
Rogan mentioned “Ozempic face” while discussing conspicuous weight loss. The exchange used a brand name and social observation; it was not a clinical assessment of facial change or a recommendation.
Scientific Context
Ozempic is FDA-approved semaglutide for type 2 diabetes and cardiovascular-risk reduction in specified patients. The colloquial phrase describes appearance after substantial weight loss and is not a distinct diagnosis unique to semaglutide.
Where to buy for laboratory research
No laboratory product is linked because the speaker named a regulated prescription brand; a research vial must not be presented as Ozempic. No substitute or near-match is linked.
Sources and limitations
- Official PowerfulJRE #2469 upload — primary source for episode number, guest, March 18, 2026 upload date and full transcript
- ClinicalTrials.gov retatrutide study record — primary trial-registry context for its investigational status
- FDA Ozempic prescribing information — approved semaglutide indications and safety information
- PubMed review of BPC-157 — peer-reviewed overview of the largely preclinical soft-tissue evidence
Research and educational use only. Most compounds discussed here are not FDA-approved to treat injury, improve performance, or extend lifespan. Laboratory supplier links are editorial references only. Nothing here is medical advice, a dosing guide, or a recommendation for human use.